Adeponle, A. B., Obembe, A. O., Adeyemi, S. O., & Suleiman, G. T. (2007). Polypharmacy in psychiatric out-patient practice in northern Nigeria. African journal of psychiatry, 10(4), 215–218. https://pubmed.ncbi.nlm.nih.gov/19588029/
Boskailo, E., Malkoc, A., McCurry, D. B., Venter, J., Drachman, D., & Ramos, G. M. (2017). Assessment of inpatient psychiatric readmission risk among patients discharged on an antipsychotic polypharmacy regimen: A retrospective cohort study. Acta medica academica, 46(2), 133–144. https://doi.org/10.5644/ama2006-124.198
Centorrino, F., Goren, J. L., Hennen, J., Salvatore, P., Kelleher, J. P., & Baldessarini, R. J. (2004). Multiple versus single antipsychotic agents for hospitalized psychiatric patients: case-control study of risks versus benefits. The American journal of psychiatry, 161(4), 700–706. https://doi.org/10.1176/appi.ajp.161.4.700
Constantine, R. J., Boaz, T., & Tandon, R. (2010). Antipsychotic polypharmacy in the treatment of children and adolescents in the fee-for-service component of a large state Medicaid program. Clinical therapeutics, 32(5), 949–959. https://doi.org/10.1016/j.clinthera.2010.04.021
Crabtree, B. L., Dostrow, V. G., Evans, C. J., Cuffel, B. J., Alvir, J. M., & Sanders, K. N. (2011). Outcome assessment of an antipsychotic drug algorithm: effects of the Mississippi State Hospital algorithm project. Psychiatric services (Washington, D.C.), 62(8), 963–965. https://doi.org/10.1176/ps.62.8.pss6208_0963
Fares M.S Muthanna, Zainal ZA, Che Mi N, & Paneerselvam GS. (2018). The usage of antipsychotic polypharmacy to treat patients with schizo-phrenia and other psychiatric disorders in Hospital Kajang. International Journal of Research in Pharmaceutical Sciences, 9(4), 1497-1503. https://doi.org/ 10.26452/ijrps.v9i4.1709
Faries, D., Ascher-Svanum, H., Zhu, B., Correll, C., & Kane, J. (2005). Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics. BMC psychiatry, 5, 26. https://doi.org/10.1186/1471-244X-5-26
Ginovart, N., & Kapur, S. (2012). Role of dopamine D(2) receptors for antipsychotic activity. Handbook of experimental pharmacology, (212), 27–52. https://doi.org/10.1007/978-3-642-25761-2_2
Igbinomwanhia, N. G., Olotu, S. O., & James, B. O. (2017). Prevalence and correlates of antipsychotic polypharmacy among outpatients with schizophrenia attending a tertiary psychiatric facility in Nigeria. Therapeutic advances in psychopharmacology, 7(1), 3–10. https://doi.org/10.1177/2045125316672134
Kelleher, J. P., & Baldessarini, R. J. (2004). Multiple versus single antipsychotic agents for hospitalized psychiatric patients: case-control study of risks versus benefits. The American journal of psychiatry, 161(4), 700–706. https://doi.org/10.1176/appi.ajp.161.4.700
Koen, L., Magni, P., Niehaus, D. J., & le Roux, A. (2008). Antipsychotic prescription patterns in Xhosa patients with schizophrenia or schizoaffective disorder. African journal of psychiatry, 11(4), 287–290.
Kumra, S., Kranzler, H., Gerbino-Rosen, G., Kester, H. M., DeThomas, C., Cullen, K., Regan, J., & Kane, J. M. (2008). Clozapine versus "high-dose" olanzapine in refractory early-onset schizophrenia: an open-label extension study. Journal of child and adolescent psychopharmacology, 18(4), 307–316. https://doi.org/10.1089/cap.2007.0089
Muthanna, Fares Mohammed Saeed. ANTIPSYCHOTIC POLYPHARMACY (INCIDENCE, IMPORTANCE AND SIDE EFFECTS), vol. 2, no. 7, 2021.
Lerma-Carrillo, I., de Pablo Brühlmann, S., del Pozo, M. L., Pascual-Pinazo, F., Molina, J. D., & Baca-García, E. (2008). Antipsychotic polypharmacy in patients with schizophrenia in a brief hospitalization unit. Clinical Neuropharmacology, 31(6), 319–332. https://doi.org/10.1097/WNF.0b013e31815cba78
Millier, A., Sarlon, E., Azorin, J. M., Boyer, L., Aballea, S., Auquier, P., & Toumi, M. (2011). Relapse according to antipsychotic treatment in schizophrenic patients: a propensity-adjusted analysis. BMC psychiatry, 11, 24. https://doi.org/10.1186/1471-244X-11-24
Muthanna FMS, Zainal ZA, Che Mi N, Paneerselvam GS (2018) Antipsychotic Polypharmacy among Psychiatric Patients in Hospital Kajang, Malaysia. J Neurol Disord 6: 374 . https://www.hilarispublisher.com/abstract/antipsychotic-polypharmacy-among-psychiatric-patients-in-hospital-kajang-malaysia-37604.html
Pae C. U. (2020). Antipsychotic Polypharmacy in Treatment of Schizophrenia; Should or Should Not?. Chonnam medical journal, 56(3), 157–165. https://doi.org/10.4068/cmj.2020.56.3.157
Santone, G., Bellantuono, C., Rucci, P., Picardi, A., Preti, A., & de Girolamo, G. (2011). Patient characteristics and process factors associated with antipsychotic polypharmacy in a nationwide sample of psychiatric inpatients in Italy. Pharmacoepidemiology and drug safety, 20(5), 441–449. https://doi.org/10.1002/pds.2083
Sim, K., Su, A., Fujii, S., Yang, S. Y., Chong, M. Y., Ungvari, G. S., Si, T., Chung, E. K., Tsang, H. Y., Chan, Y. H., Heckers, S., Shinfuku, N., & Tan, C. H. (2004). Antipsychotic polypharmacy in patients with schizophrenia: a multicentre comparative study in East Asia. British journal of clinical pharmacology, 58(2), 178–183. https://doi.org/10.1111/j.1365-2125.2004.02102.x
Steinberg L. (2008). A Social Neuroscience Perspective on Adolescent Risk-Taking. Developmental review : DR, 28(1), 78–106. https://doi.org/10.1016/j.dr.2007.08.002
Suokas, J. T., Suvisaari, J. M., Haukka, J., Korhonen, P., & Tiihonen, J. (2013). Description of long-term polypharmacy among schizophrenia outpatients. Social psychiatry and psychiatric epidemiology, 48(4), 631–638. https://doi.org/10.1007/s00127-012-0586-6
Tesfaye, S., Debencho, N., Kisi, T., & Tareke, M. (2016). Prevalence of Antipsychotic Polypharmacy and Associated Factors among Outpatients with Schizophrenia Attending Amanuel Mental Specialized Hospital, Addis Ababa, Ethiopia. Psychiatry journal, 2016, 6191074. https://doi.org/10.1155/2016/6191074
Waddington, J. L., Youssef, H. A., & Kinsella, A. (1995). Sequential cross-sectional and 10-year prospective study of severe negative symptoms in relation to duration of initially untreated psychosis in chronic schizophrenia. Psychological medicine, 25(4), 849–857. https://doi.org/10.1017/s0033291700035108
Yang, S. Y., Chen, L. Y., Najoan, E., Kallivayalil, R. A., Viboonma, K., Jamaluddin, R., Lin, S. K.. et al (2018). Polypharmacy and psychotropic drug loading in patients with schizophrenia in Asian countries: Fourth survey of Research on Asian Prescription Patterns on antipsychotics. Psychiatry and clinical neurosciences, 72(8), 572–579. https://doi.org/10.1111/pcn.12676